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Abstract
High cytogenetic risk abnormalities confer poor outcomes in multiple myeloma patients. In POLLUX, daratumumab/
lenalidomide/dexamethasone (D-Rd) demonstrated significant clinical benefit versus lenalidomide/dexamethasone
(Rd) in relapsed/refractory multiple myeloma (RRMM) patients. We report an updated subgroup analysis of POLLUX
based on cytogenetic risk. The cytogenetic risk was determined using fluorescence in situ hybridization/karyotyping;
patients with high cytogenetic risk had t(4;14), t(14;16), or del17p abnormalities. Minimal residual disease (MRD; 10–5)
was assessed via the clonoSEQ® assay V2.0. 569 patients were randomized (D-Rd, n= 286; Rd, n= 283); 35 (12%)
patients per group had high cytogenetic risk. After a median follow-up of 44.3 months, D-Rd prolonged progression-
free survival (PFS) versus Rd in standard cytogenetic risk (median: not estimable vs 18.6 months; hazard ratio [HR], 0.43;
P < 0.0001) and high cytogenetic risk (median: 26.8 vs 8.3 months; HR, 0.34; P= 0.0035) patients. Responses with D-Rd
were deep, including higher MRD negativity and sustained MRD-negativity rates versus Rd, regardless of cytogenetic
risk. PFS on subsequent line of therapy was improved with D-Rd versus Rd in both cytogenetic risk subgroups. The
safety profile of D-Rd by cytogenetic risk was consistent with the overall population. These findings demonstrate the
improved efficacy of daratumumab plus standard of care versus standard of care in RRMM, regardless of
cytogenetic risk.
Introduction
Daratumumab is a human IgGκ monoclonal antibody
targeting CD38 with a direct on-tumor1–4 and immuno-
modulatory5–7 mechanism of action. Intravenous dar-
atumumab 16mg/kg is approved in the USA in
combination with lenalidomide and dexamethasone (Rd)
or bortezomib and dexamethasone (Vd) in patients with
multiple myeloma (MM) who received at least one prior
line of therapy, in combination with bortezomib/mel-
phalan/prednisone or Rd in patients with transplant-
ineligible newly diagnosed MM, and in combination with
bortezomib, thalidomide, and dexamethasone in patients
with transplant-eligible newly diagnosed MM8. Dar-
atumumab is also approved in the USA as monotherapy in
patients with heavily pretreated relapsed or refractory
MM (RRMM) and in combination with pomalidomide/
dexamethasone for patients with at least two prior
therapies, including lenalidomide and a proteasome
inhibitor8.
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In the phase 3 POLLUX study in patients with RRMM,
adding daratumumab to Rd (D-Rd) more than doubled
complete response (CR) or better rates, induced a > four-
fold increase in the rate of minimal residual disease
(MRD) negativity at the 10–5 sensitivity threshold, and
reduced the risk of disease progression or death by 63%
versus Rd alone at a median follow-up of 13.5 months9.
With longer follow-up (median: 44.3 months), D-Rd
continued to reduce the risk of disease progression or
death by 56% and significantly increased the overall
response rate (ORR; 93% vs 76%; P < 0.0001) and rates of
CR or better (57% vs 23%; P < 0.0001), very good partial
response (VGPR) or better (80% vs 49%; P < 0.0001), and
MRD negativity (10–5 sensitivity threshold; 30% vs 5%;
P < 0.000001) versus Rd alone10.
Patients with MM and high cytogenetic risk abnormal-
ities including IgH translocations (e.g., t[4;14]) and geno-
mic imbalance (e.g., del17p) have worse progression-free
survival (PFS) and overall survival outcomes compared
with patients with standard cytogenetic risk11,12. Although
high cytogenetic risk abnormalities are most relevant as a
prognostic marker prior to relapse, several studies have
shown that they have a negative effect on survival for
RRMM11,12. The 2009 International Myeloma Working
Group (IMWG) guidelines define high cytogenetic risk as
having at least one of the following abnormalities: t(4;14),
t(14;16), or del17p, determined by fluorescence in situ
hybridization (FISH)13. More recently, and after the
POLLUX study was initiated, updated IMWG guidelines
were published in 2016, wherein the definition of high
cytogenetic risk was expanded to include t(14;20) and
gain1q abnormalities11. In patients with high cytogenetic
risk, treatment choice is driven by the duration, quality,
and depth of response offered; updated IMWG guidelines
recommend treatment with regimens containing borte-
zomib or lenalidomide in these patients.
After a median follow-up of 25.4 months, D-Rd sig-
nificantly prolonged PFS and increased ORR in patients
with RRMM in POLLUX; improvement was also seen
regardless of cytogenetic risk status14. Here, we report the
updated efficacy and safety findings after a median follow-
up of more than 3 years for patients with standard and
high cytogenetic risk RRMM.
Methods
Patients
A total of 439 patients who underwent cytogenetic testing
from phase 3 POLLUX study (ClinicalTrials.gov identifier:
NCT02076009) were included in this analysis. The study
design, complete eligibility criteria, and primary and sub-
group analysis results have been previously published9,14.
Briefly, eligible patients were ≥18 years of age with an
Eastern Cooperative Oncology Group performance status
score of 0 to 2. Patients had received at least one prior line of
therapy for MM, achieved at least a partial response to at
least one prior MM therapy, and had documented evidence
of progressive disease based on IMWG criteria on or after
their last regimen. Patients were excluded if they were
refractory to or intolerant of lenalidomide or had a creati-
nine clearance of <30mL/min/1.73m2.
Study design and treatment
POLLUX is a phase 3, randomized, open-label, active-
controlled, multicenter study in patients with RRMM.
Randomization was stratified according to International
Staging System (ISS) disease stage (I vs II vs III) at
screening, number of prior lines of therapy (1 vs 2 or 3 vs
>3), and prior lenalidomide exposure (no vs yes).
Exploratory analyses were conducted for subgroups of
patients based on cytogenetic risk status. Patients were
randomized 1:1 to Rd (lenalidomide: 25 mg orally on Days
1–21 of each 28-day cycle; dexamethasone: 40 mg orally
weekly) with or without daratumumab (16 mg/kg IV
weekly for 8 weeks, every 2 weeks for 16 weeks, and then
every 4 weeks) until progression.
Cytogenetic risk evaluation
Cytogenetic abnormalities were detected by local FISH
or karyotyping on bone marrow aspirates collected at
screening visits. Determination of each abnormality and
threshold of frequencies to consider a positive finding was
determined locally and varied by site. Patients in the
intent-to-treat (ITT) population who had at least one
assessment from FISH or karyotyping were included in
the analysis. Patients with high cytogenetic risk status had
at least one of the following cytogenetic abnormalities
identified: t(4;14), t(14;16), or del17p.
MRD evaluation
MRD was assessed at the time of the suspected CR
(including stringent CR; blinded to treatment group), and
if CR was maintained, at 3 months, 6 months, and every
12 months after confirmation of CR. MRD testing was
performed via the clonoSEQ® assay V2.0 (Adaptive Bio-
technologies, Seattle, WA, USA) at the 10–5 sensitivity
threshold (one cancer cell per 100,000 nucleated cells).
Patients with an MRD-negative test result were con-
sidered to be MRD negative, and patients with only MRD-
positive or indeterminate test results or who had not
undergone MRD testing were considered to be MRD
positive. Sustained MRD negativity was defined as con-
firmed maintenance of MRD-negative status at a sensi-
tivity threshold of 10–5 for ≥6 or ≥12 months.
Statistical analyses and assessments
PFS analyses for the cytogenetic risk groups included
patients in the ITT population who met the biomarker
criteria for risk assessment. Patients with measurable
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disease at baseline or at the screening visit who received at
least one study treatment and had undergone at least one
post-baseline disease assessment were included in the
response-evaluable population. Patients who received at
least one administration of study treatment were included
in the safety population.
PFS and time to response were compared between the D-
Rd and Rd treatment groups using a stratified log-rank test.
Hazard ratios (HRs) and 95% confidence intervals (CIs) were
estimated using a Cox proportional hazards model with
treatment as the sole explanatory variable. The
Kaplan–Meier method was used to estimate the distribu-
tions. PFS on the subsequent line of therapy (PFS2) was
defined as the time from randomization to disease pro-
gression after the next line of subsequent therapy or death.
Differences in ORRs, rates of CR or better, and rates of
VGPR or better between treatment groups were measured
using a stratified Cochran–Mantel–Haenszel chi-square test.
MRD and sustained MRD negativity were evaluated for
patients in the entire ITT population who met the bio-
marker criteria for risk assessment to allow for a stringent
and unbiased evaluation of MRD negativity. MRD-
negativity rates were defined as the proportion of
patients who achieved MRD-negative status at any time
point following the first treatment dose. A Fisher’s exact
test was used to compare MRD-negativity rates between
the D-Rd and Rd treatment groups.
Study oversight
Institutional review boards or ethics committees
approved the research at each clinical study site. All
patients provided written informed consent. The study
design and analyses were devised by the investigators and
sponsor, and study data were collected by the investigators
and their research teams. Final data analysis and verifica-
tion of accuracy were conducted by Janssen. The investi-
gators were not restricted by confidentiality agreements
and had full accessibility to all the data. Writing assistance
was funded by Janssen Global Services. The study was
sponsored by Janssen Research & Development, LLC and
was registered at ClinicalTrials.gov (NCT02076009).
Data-sharing statement
The data-sharing policy of Janssen Pharmaceutical
Companies of Johnson & Johnson is available at https://
www.janssen.com/clinical-trials/transparency. As noted
on this site, requests for access to the study data can be
submitted through the Yale Open Data Access Project site
at http://yoda.yale.edu.
Results
Patients and treatments
A total of 569 patients were randomized, with 286
assigned to D-Rd and 283 to Rd. A total of 439 (77%)
patients underwent cytogenetic testing; 324 (57%) patients
were evaluated using FISH, 261 (46%) patients were
evaluated using karyotyping, and 146 (26%) were eval-
uated using both. Of these, high cytogenetic risk
abnormalities were reported in 35 (12%) patients in the
D-Rd group and 35 (12%) patients in the Rd group. The
standard cytogenetic risk was reported in 193 (68%)
patients in the D-Rd group and 176 (62%) patients in the
Rd group. Among patients assessed for cytogenetic risk,
patient demographics, baseline disease, and clinical
characteristics based on cytogenetic status are shown in
Table 1. Among patients achieving CR or better, MRD
was not evaluated in 48 (22%) patients. At the time of the
clinical cutoff (October 10, 2018), 253 (69%) and 57 (83%)
patients discontinued treatment in the standard and high
cytogenetic risk subgroups, respectively (Table 2).
Updated efficacy results
After a median follow-up of 44.3 months, D-Rd pro-
longed PFS versus Rd in patients with standard cytoge-
netic risk (median: not estimable [NE] vs 18.6 months;
HR, 0.43; 95% CI, 0.32–0.57; P < 0.0001; Fig. 1A) and high
cytogenetic risk (median: 26.8 months vs 8.3 months; HR,
0.34; 95% CI, 0.16–0.72; P= 0.0035; Fig. 1B) in the ITT
population. The 42-month PFS rates were 53% with D-Rd
versus 25% with Rd in the standard cytogenetic risk
subgroup and 35% versus 13%, respectively, in the high
cytogenetic risk subgroup. Among patients with 1 prior
line of therapy, D-Rd prolonged PFS versus Rd in patients
with standard cytogenetic risk (median: NE vs
20.2 months; HR, 0.41; 95% CI, 0.27–0.63; P < 0.0001; 42-
month PFS rate: 58% vs 27%; Fig. 1C) and high cytoge-
netic risk (median: 29.6 months vs 6.6 months; HR, 0.26;
95% CI, 0.09–0.75; P= 0.0083; 42-month PFS rate: 43% vs
12%; Fig. 1D).
The ORR and rates of VGPR or better and CR or better
were higher with D-Rd compared with Rd, regardless of
cytogenetic risk status (Table 3). Among patients with
standard cytogenetic risk, time to VGPR or better (med-
ian: 3.7 vs 8.3 months; HR, 1.98; 95% CI, 1.52–2.59;
P < 0.0001) and CR or better (median: 13.9 months vs NE;
HR, 2.38; 95% CI, 1.66–3.43; P < 0.0001) were decreased
with D-Rd versus Rd. Time to VGPR or better (median:
3.7 months vs 18.7 months; HR, 3.45; 95% CI, 1.41–8.39;
P= 0.0040) and CR or better (median: 14.4 months vs NE;
HR, 2.07; 95% CI, 0.51–8.48; P= 0.3011) were also
decreased with D-Rd versus Rd for patients with high
cytogenetic risk.
At a sensitivity threshold of 10–5, MRD-negativity rates
were higher with D-Rd compared with Rd, regardless of
cytogenetic risk (Table 3). Nine patients with high-risk
cytogenetics in the D-Rd group achieved MRD negativity;
however, only one of these patients was able to sustain
this response. No patients in the Rd group who had a
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high-risk cytogenetic feature achieved MRD negativity.
MRD negativity was sustained for at least 6 months and at
least 12 months in 18% and 14% of patients treated with
D-Rd, respectively, versus 1% of patients treated with Rd
in the standard cytogenetic risk subgroup (Table 3).
D-Rd prolonged PFS2 versus Rd in both standard
cytogenetic risk (median: NE vs 33.3 months; HR, 0.54;
95% CI, 0.40–0.74; P < 0.0001; Fig. 2A) and high cytoge-
netic risk (median: 37.7 months vs 20.8 months; HR, 0.38;
95% CI, 0.18–0.83; P= 0.0121) subgroups (Fig. 2B).
Among patients with one prior line of therapy, PFS2 was
prolonged with D-Rd versus Rd in patients with standard
cytogenetic risk (median: NE vs 38.2 months; HR, 0.53;
95% CI, 0.34–0.83; P= 0.0049; Fig. 2C) and high cytoge-
netic risk (median: 36.2 months vs 16.9 months; HR, 0.26;
95% CI, 0.09–0.74; P= 0.0082; Fig. 2D).
At the time of the analysis, among patients with stan-
dard cytogenetic risk, 71 (36.8%) deaths were observed in
the D-Rd group versus 68 (38.6%) deaths in the Rd group.
Among patients with high cytogenetic risk, 18 (51.4%)
deaths were observed in the D-Rd group versus 22 (62.9%)
deaths in the Rd group. The overall survival data were
immature, and follow-up for overall survival is ongoing.
Safety
The most common (≥25% of patients) any-grade treat-
ment-emergent adverse events (TEAEs) and most com-
mon (≥5% of patients) grade 3/4 TEAEs are summarized
in Table 4. The most common hematologic adverse event
was neutropenia, followed by anemia and thrombocyto-
penia. The most common infection was upper respiratory
tract infection, followed by nasopharyngitis and
pneumonia.
Discussion
After more than 3 years of follow-up, D-Rd continued
to demonstrate improved efficacy versus Rd alone in
patients with RRMM regardless of cytogenetic risk status;
Table 1 Patient demographics, baseline disease, and
clinical characteristics.
Standard cytogenetic risk* High cytogenetic risk*,†
Characteristic D-Rd
(n= 193)
Rd (n= 176) D-Rd
(n= 35)
Rd (n= 35)
Age, y
Median (range) 66 (36–89) 64 (42–85) 67 (50–80) 67 (50–81)
≥75 y, n (%) 21 (11) 17 (10) 4 (11) 6 (17)
Sex, n (%)
Male 114 (59) 102 (58) 19 (54) 19 (54)
Race, n (%)
White 131 (68) 120 (68) 28 (80) 23 (66)
Asian 47 (24) 35 (20) 4 (11) 8 (23)
Black or African American 4 (2) 5 (3) 1 (3) 2 (6)
Unknown/not reported 11 (6) 16 (9) 2 (6) 2 (6)
ISS stage,‡ n (%)
I 96 (50) 92 (52) 13 (37) 14 (40)
II 62 (32) 50 (28) 15 (43) 13 (37)
III 35 (18) 34 (19) 7 (20) 8 (23)
ECOG performance status score, n (%)
0 94 (49) 90 (51) 15 (43) 22 (63)
1 91 (47) 78 (44) 18 (51) 12 (34)
2 8 (4) 8 (5) 2 (6) 1 (3)
Cytogenetic profile,*,† n (%)
t(4;14) – – 10 (29) 15 (43)
t(14;16) – – 2 (6) 6 (17)
del17p – – 25 (71) 20 (57)
≥2 risk factors§ – – 2 (6) 5 (14)
Median (range) time from
diagnosis, y
3.7 (0.6–22.5) 4.0 (0.4–18.3) 3.2 (0.4–27.0) 2.3 (0.4–14.6)
Prior lines of therapy, n (%)
1 96 (50) 90 (51) 22 (63) 20 (57)
2 62 (32) 47 (27) 6 (17) 9 (26)
3 24 (12) 24 (14) 5 (14) 4 (11)
>3 11 (6) 15 (9) 2 (6) 2 (6)
Median (range) 2 (1–11) 1 (1–8) 1 (1–6) 1 (1–6)
Prior ASCT, n (%) 115 (60) 115 (65) 22 (63) 19 (54)
Prior PI, n (%) 162 (84) 148 (84) 31 (89) 31 (89)
Bortezomib 160 (83) 145 (82) 30 (86) 31 (89)
Prior IMiD, n (%) 103 (53) 102 (58) 22 (63) 15 (43)
Lenalidomide 27 (14) 33 (19) 10 (29) 4 (11)
Prior PI+ IMiD, n (%) 79 (41) 80 (46) 18 (51) 12 (34)
Refractory to PI only, n (%) 42 (22) 29 (17) 8 (23) 9 (26)
Refractory to IMiD only, n (%) 7 (4) 10 (6) 3 (9) 1 (3)
Refractory to PI and IMiD, n
(%)
6 (3) 7 (4) 1 (3) 3 (9)
Refractory to last line of
therapy, n (%)
62 (32) 50 (28) 11 (31) 13 (37)
D-Rd daratumumab plus lenalidomide/dexamethasone, Rd lenalidomide/dex-
amethasone, ISS International Staging System, ECOG Eastern Cooperative
Oncology Group, ASCT autologous stem cell transplant, PI proteasome inhibitor,
IMiD immunomodulatory drug, FISH fluorescence in situ hybridization.
Note: percentages may not equal 100% due to rounding.
*Based on FISH/karyotyping.
†Patients with high cytogenetic risk had a t(4;14), t(14;16), or del17p abnormality.
‡ISS stage is derived based on the combination of serum β2-microglobulin and
albumin.
§Patients with ≥2 of the t(4;14), t(14;16), or del17p risk factors.
Table 2 Patient disposition based on cytogenetic risk*
status.
Standard risk High risk†
Treatment discontinuation,‡
n (%)
D-Rd
(n= 192)
Rd
(n= 176)
D-Rd
(n= 35)
Rd
(n= 34)
Patients who discontinued
treatment
105 (55) 148 (84) 26 (74) 31 (91)
Reason for discontinuation
Progressive disease 57 (30) 104 (59) 17 (49) 25 (74)
Adverse event 28 (15) 22 (13) 7 (20) 4 (12)
Noncompliance with study
drug§
7 (4) 4 (2) 0 2 (6)
Withdrawal by patient 2 (1) 8 (5) 1 (3) 0
Physician decision 6 (3) 3 (2) 1 (3) 0
Death 3 (2) 5 (3) 0 0
Other 2 (1) 2 (1) 0 0
D-Rd daratumumab plus lenalidomide/dexamethasone, Rd lenalidomide/dex-
amethasone, FISH fluorescence in situ hybridization.
*Based on FISH/karyotyping.
†Patients with high cytogenetic risk had a t(4;14), t(14;16), or del17p abnormality.
‡Safety population.
§Based on reason, “patient refused to further study treatment” at “end of
treatment.”
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No. at risk
Rd standard risk
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176
193
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157
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5
14
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133
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128
58
117
54
109
49
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42
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No. at risk
Rd standard risk
D-Rd standard risk
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96
84
89
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85
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49
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0
0
8
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21
52
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44
39
67
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66
32
62
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D-Rd high risk:
Median 29.6 mo
Rd high risk:
Median 6.6 mo
High risk: HR, 0.34; 95% CI, 0.16–0.72; P = 0.0035
High risk: HR, 0.26; 95% CI, 0.09–0.75; P = 0.0083
D-Rd high risk:
Median 26.8 mo
Rd high risk:
Median 8.3 mo
D-Rd standard risk
Rd standard risk:
Median 20.2 mo
D-Rd standard risk
Standard risk: HR, 0.43; 95% CI, 0.32–0.57; P < 0.0001
Standard risk: HR, 0.41; 95% CI, 0.27–0.63; P < 0.0001
Rd standard risk:
Median 18.6 mo
Fig. 1 PFS based on cytogenetic risk status. PFS in the ITT/biomarker risk population:* A standard and B high cytogenetic risk patients. PFS in
patients with one prior line of therapy: C standard and D high cytogenetic risk patients. PFS progression-free survival, HR hazard ratio, CI confidence
interval, D-Rd daratumumab plus lenalidomide/dexamethasone, Rd lenalidomide/dexamethasone, ITT intent-to-treat. *Patients in the ITT population
who met the biomarker criteria for risk assessment.
Table 3 Response and MRD-negativity rates in patients with standard and high cytogenetic risk.
Standard risk High risk*
Response,† n (%) D-Rd (n= 190) Rd (n= 172) P D-Rd (n= 35) Rd (n= 34) P
ORR 178 (94) 135 (79) <0.0001 31 (89) 23 (68) 0.0145
≥CR 111 (58) 43 (25) 15 (43) 3 (9)
Stringent CR 61 (32) 23 (13) 10 (29) 1 (3)
CR 50 (26) 20 (12) 5 (14) 2 (6)
≥VGPR 156 (82) 92 (54) <0.0001 25 (71) 10 (29) 0.0004
VGPR 45 (24) 49 (29) 10 (29) 7 (21)
PR 22 (12) 43 (25) 6 (17) 13 (38)
MRD negative (10–5)‡ n= 193 n= 176 n= 35 n= 35
n (%) 63 (33) 15 (9) <0.0001 9 (26) 0 0.0022
Sustained MRD negativity (≥6 months), n (%) 35 (18) 2 (1) <0.0001 1 (3) 0
Sustained MRD negativity (≥12 months), n (%) 27 (14) 1 (1) <0.0001 1 (3) 0
MRD minimal residual disease, D-Rd daratumumab plus lenalidomide/dexamethasone, Rd lenalidomide/dexamethasone, ORR overall response rate, CR complete
response, VGPR very good partial response, PR partial response, ITT intent-to-treat.
*Patients with high cytogenetic risk had a t(4;14), t(14;16), or del17p abnormality.
†Response-evaluable population.
‡ITT population.
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however, as has been observed previously for high-risk
patients, this subgroup had poorer outcomes in both
treatment arms. At a median follow-up of 44.3 months,
D-Rd reduced the risk of disease progression or death by
57% versus Rd alone in patients with standard cytogenetic
risk and by 66% in patients with high cytogenetic risk.
Median PFS for patients treated with D-Rd was NE in
those with standard cytogenetic risk (vs 18.6 months with
Rd; P < 0.0001) and was 26.8 months in those with high
cytogenetic risk (vs 8.3 months with Rd; P= 0.0035).
Similar results were observed in the subset of patients
with one prior line of therapy. Deep responses were
observed with D-Rd in both patients with standard cyto-
genetic risk (≥CR: 58% vs 25% with Rd) and high cyto-
genetic risk (≥CR: 43% vs 9% with Rd). Time to reach
VGPR or better and CR or better was decreased with
D-Rd compared with Rd in both the standard and high
cytogenetic risk subgroups. Regardless of cytogenetic risk,
MRD-negativity (10–5) rates were higher with D-Rd ver-
sus Rd, and more patients treated with D-Rd achieved a
sustained MRD response, which translates into better
patient outcomes15, suggesting that achievement of MRD
negativity can predict clinical benefit across all patient risk
groups. In addition, PFS2 was prolonged with D-Rd
compared with Rd in the ITT population and in patients
with one prior line of therapy, regardless of cytogenetic
risk status. Of note, although favorable outcomes were
achieved by D-Rd in patients with high cytogenetic risk,
clinical benefits were of lesser magnitude than in patients
with standard cytogenetic risk, demonstrating that D-Rd
reduces but does not abrogate the adverse impact of high-
risk cytogenetics.
This extended follow-up of POLLUX complements the
results reported after a median follow-up of
25.4 months14. In the earlier analysis, D-Rd reduced the
risk of disease progression or death by 70% versus Rd
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Fig. 2 PFS2 based on cytogenetic risk status. PFS2 in the ITT/biomarker risk population:* A standard and B high cytogenetic risk patients. PFS2 in
patients with one prior line of therapy: C standard and D high cytogenetic risk patients. PFS2 progression-free survival on the next subsequent line of
therapy, D-Rd daratumumab plus lenalidomide/dexamethasone, Rd lenalidomide/dexamethasone, HR hazard ratio, CI confidence interval, ITT intent-
to-treat. *Patients in the ITT population who met the biomarker criteria for risk assessment.
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Table 4 Most common any-grade (≥25% of patients) and Grade 3/4 (≥5% of patients) TEAEs.
Any grade Grade 3/4
Standard risk High risk* Standard risk High risk*
TEAE, n (%) D-Rd
(n= 192)
Rd
(n= 176)
D-Rd
(n= 35)
Rd
(n= 34)
D-Rd
(n= 192)
Rd
(n= 176)
D-Rd
(n= 35)
Rd
(n= 34)
Hematologic
Neutropenia 116 (60) 80 (46) 22 (63) 18 (53) 103 (54) 69 (39) 17 (49) 16 (47)
Febrile neutropenia 10 (5) 4 (2) 2 (6) 0 10 (5) 4 (2) 2 (6) 0
Anemia 71 (37) 62 (35) 13 (37) 15 (44) 31 (16) 32 (18) 7 (20) 10 (29)
Thrombocytopenia 55 (29) 46 (26) 13 (37) 14 (41) 25 (13) 24 (14) 8 (23) 10 (29)
Leukopenia 18 (9) 15 (9) 3 (9) 4 (12) 6 (3) 4 (2) 1 (3) 3 (9)
Lymphopenia 10 (5) 10 (6) 5 (14) 3 (9) 8 (4) 7 (4) 5 (14) 3 (9)
Nonhematologic
Diarrhea 104 (54) 53 (30) 18 (51) 16 (47) 20 (10) 5 (3) 3 (9) 4 (12)
Upper respiratory tract
infection
82 (43) 56 (32) 10 (29) 8 (24) 4 (2) 3 (2) 0 0
Fatigue 74 (39) 52 (30) 12 (34) 12 (35) 13 (7) 9 (5) 4 (11) 2 (6)
Cough 65 (34) 23 (13) 11 (31) 6 (18) 0 0 0 0
Nasopharyngitis 64 (33) 37 (21) 11 (31) 9 (27) 0 0 0 0
Constipation 57 (30) 46 (26) 12 (34) 10 (29) 0 1 (1) 2 (6) 1 (3)
Insomnia 54 (28) 41 (23) 9 (26) 4 (12) 5 (3) 3 (2) 0 1 (3)
Muscle spasms 52 (27) 36 (21) 12 (34) 7 (21) 2 (1) 3 (2) 1 (3) 0
Pneumonia 51 (27) 30 (17) 10 (29) 6 (18) 32 (17) 20 (11) 4 (11) 4 (12)
Nausea 48 (25) 37 (21) 14 (40) 8 (24) 5 (3) 2 (1) 1 (3) 0
Peripheral edema 47 (25) 24 (14) 8 (23) 3 (9) 1 (1) 1 (1) 0 0
Pyrexia 48 (25) 18 (10) 10 (29) 5 (15) 5 (3) 5 (3) 1 (3) 1 (3)
Dyspnea 37 (19) 23 (13) 7 (20) 4 (12) 2 (1) 1 (1) 4 (11) 0
Hypokalemia 37 (19) 19 (11) 7 (20) 4 (12) 14 (7) 5 (3) 2 (6) 1 (3)
Cataract 35 (18) 24 (14) 4 (11) 2 (6) 13 (7) 8 (5) 1 (3) 1 (3)
Bronchitis 32 (17) 24 (14) 10 (29) 4 (12) 6 (3) 5 (3) 0 0
Arthralgia 27 (14) 22 (13) 10 (29) 5 (15) 2 (1) 1 (1) 1 (3) 0
Influenza 20 (10) 9 (5) 5 (14) 2 (6) 2 (1) 0 2 (6) 0
Hyperglycemia 18 (9) 14 (8) 6 (17) 3 (9) 5 (3) 7 (4) 4 (11) 2 (6)
Hypophosphatemia 12 (6) 7 (4) 4 (11) 2 (6) 9 (5) 5 (3) 3 (9) 0
Hypertension 12 (6) 8 (5) 9 (26) 2 (6) 5 (3) 2 (1) 4 (11) 0
Increased alanine
aminotransferase
12 (6) 7 (4) 5 (14) 3 (9) 6 (3) 2 (1) 2 (6) 1 (3)
Syncope 9 (5) 2 (1) 2 (6) 1 (3) 9 (5) 2 (1) 2 (6) 1 (3)
Pulmonary embolism 4 (2) 8 (5) 2 (6) 2 (6) 4 (2) 7 (4) 2 (6) 2 (6)
Hypercalcemia 2 (1) 6 (3) 3 (9) 2 (6) 1 (1) 2 (1) 2 (6) 2 (6)
TEAE treatment-emergent adverse event, D-Rd daratumumab plus lenalidomide/dexamethasone, Rd lenalidomide/dexamethasone.
*Patients with high cytogenetic risk had a t(4;14), t(14;16), or del17p abnormality.
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alone in patients with standard cytogenetic risk (D-Rd,
n= 133; Rd, n= 113) and by 47% in patients with high
cytogenetic risk (D-Rd, n= 28; Rd, n= 37), with cytoge-
netic abnormalities assessed by central next-generation
sequencing14. The next-generation sequencing and FISH
methods have been shown to have high concordance
(88%–98%) in identifying high-risk cytogenetics16.
The safety profile of D-Rd in the standard and high
cytogenetic risk subgroups was consistent with the overall
population of POLLUX9,10. No new safety concerns were
observed following a median follow-up of more than
3 years.
Although cross-trial comparisons are limited by differ-
ences in risk-group definitions (due to lack of consensus
criteria on cutoffs), patient populations, and clinical
settings, they allow for a comprehensive assessment of a
treatment regimen’s clinical benefit. The efficacy results
in terms of HR of PFS from this study are similar to
those for other studies of the immunomodulatory drug
(IMiD)–containing regimens in patients with RRMM
and high cytogenetic risk. In a subgroup analysis of the
phase 3 ASPIRE study, among patients with high cyto-
genetic risk (defined as the presence of t[4;14], t[14;16], or
del17p according to FISH), median PFS was 23.1 months
with carfilzomib plus Rd versus 13.9 months with Rd
alone (HR, 0.70; 95% CI, 0.43–1.16; P= 0.0829)17. In the
phase 3 study of elotuzumab (ELOQUENT-2), at a
median follow-up of 46 months, median PFS among high-
risk patients (defined as ISS stage II or III disease and a t
[4;14] or del17p abnormality) was 15 months with elo-
tuzumab plus Rd compared with 7 months with Rd alone
(HR, 0.64; 95% CI, 0.43–0.97; P= 0.0331)18. In a post hoc
analysis of the TOURMALINE-MM1 study according to
cytogenetic risk status, median PFS in high-risk patients
(defined as t[4;14], t[14;16] or del17p abnormality) was
21.4 months with ixazomib plus Rd versus 9.7 months
with Rd alone (HR, 0.543; 95% CI, 0.321–0.918; P=
0.021)19. None of these analyses reported the effects of
these combinations on MRD negativity according to
cytogenetic risk status.
Improvement in PFS with a daratumumab-based regi-
men versus standard of care was also observed in the
phase 3 CASTOR study of daratumumab plus Vd (D-Vd)
versus Vd alone in RRMM, regardless of cytogenetic risk
status20. In an updated subgroup analysis after a median
follow-up of more than 3 years, treatment with D-Vd
prolonged PFS compared with Vd in patients with stan-
dard cytogenetic risk (16.6 vs 6.6 months; HR, 0.26; 95%
CI, 0.19–0.37) as well as those with high cytogenetic risk
(12.6 vs 6.2 months; HR, 0.41; 95% CI, 0.21–0.83)21. The
benefits of D-Vd over Vd in the high-risk population were
not only maintained but strengthened, demonstrating
improved clinical benefit in terms of PFS, ORR, rate of
VGPR or better, and MRD-negativity rate. Moreover,
among high-risk patients, MRD negativity was only
achieved in patients treated with D-Vd.
Although high cytogenetic risk patients in the POLLUX
study were defined using the 2009 IMWG criteria avail-
able at the time of study design instead of the updated
2016 criteria, the definition used to determine high
cytogenetic risk status (t[4;14], t[14;16], or del17p
abnormality) is consistent with the previously mentioned
studies. Additionally, the fact that among the patients
with high cytogenetic risk in this study, patients who
received Rd had a lower PFS further confirms the correct
categorization of patients.
This subgroup analysis was limited by incomplete
cytogenetic abnormality data collected for patients
enrolled in the POLLUX study; cytogenetic testing was
not performed in 23% of patients. Also, the cytogenetic
testing for t(4;14), t(14;16), and del17p abnormalities was
performed locally, and threshold levels for a positive
finding were not uniform for all patients. Although
additional abnormalities were requested, they were not
required by the protocol and were not always reported.
About two-thirds of patients with high cytogenetic risk in
this study had del17p abnormalities. The presence of
TP53 mutation status in del17p patients is known to
adversely affect clinical outcomes; however, details on
TP53 mutational status were not collected and thus a
potential for bias based on TP53 mutation status cannot
be ruled out. Small sample sizes in the cytogenetic risk
subgroups precluded us from conducting additional sub-
group analyses. MRD results were not available in 22% of
patients with CR or better. Patients without MRD
assessment were considered as MRD positive, potentially
underestimating the rate of MRD negativity.
In conclusion, the results from this updated subgroup
analysis of POLLUX show that D-Rd in comparison with
the standard of care alone improves the outcome of
patients with high-risk RRMM. Moreover, the analysis of
all the previously mentioned trials confirms that dar-
atumumab is effective in patients with MM, regardless of
cytogenetic risk status.
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